GLOBAL IMMUNOGLOBULIN MARKET FORECAST 2022-2030


 

TABLE OF CONTENTS

1.     RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES

1.2. SCOPE OF STUDY

1.3. METHODOLOGY

1.4. ASSUMPTIONS & LIMITATIONS

2.     EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES

2.2. MARKET OVERVIEW

3.     MARKET DYNAMICS

3.1. KEY DRIVERS

3.1.1. GROWTH IN GERIATRIC POPULATION

3.1.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS

3.1.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

3.2. KEY RESTRAINTS

3.2.1. HIGH COST OF THERAPY

3.2.2. HIGH RISK OF SIDE EFFECTS

4.     KEY ANALYTICS

4.1. IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET

4.2. KEY MARKET TRENDS

4.3. PORTER’S FIVE FORCES ANALYSIS

4.3.1. BUYERS POWER

4.3.2. SUPPLIERS POWER

4.3.3. SUBSTITUTION

4.3.4. NEW ENTRANTS

4.3.5. INDUSTRY RIVALRY

4.4. OPPORTUNITY MATRIX

4.5. VENDOR LANDSCAPE

4.6. KEY BUYING CRITERIA

4.6.1. SOURCE

4.6.2. APPLICATION

4.6.3. EPITOPE

4.6.4. VALIDATION

4.7. REGULATORY FRAMEWORK

5.     MARKET BY PRODUCT

5.1. IGG

5.2. IGA

5.3. IGM

5.4. IGE

5.5. IGD

6.     MARKET BY MODE OF DELIVERY

6.1. INTRAVENOUS IMMUNOGLOBULIN

6.2. SUBCUTANEOUS IMMUNOGLOBULIN

6.3. INTRAMUSCULAR IMMUNOGLOBULIN

7.     MARKET BY APPLICATION

7.1. HYPOGAMMA GLOBULINEMIA

7.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

7.3. PRIMARY IMMUNODEFICIENCY DISEASES

7.4. MYASTHENIA GRAVIS

7.5. MULTIFOCAL MOTOR NEUROPATHY

7.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

7.7. INFLAMMATORY MYOPATHIES

7.8. SPECIFIC ANTIBODY DEFICIENCY

7.9. GUILLAIN-BARRE SYNDROME

7.10. OTHER APPLICATIONS

8.     MARKET BY DISTRIBUTION CHANNEL

8.1. HOSPITAL PHARMACY

8.2. SPECIALTY PHARMACY

8.3. OTHER DISTRIBUTION CHANNELS

9.     MARKET BY END-USER

9.1. HOSPITALS & CLINICS

9.2. HOMECARE

10. GEOGRAPHICAL ANALYSIS

10.1. NORTH AMERICA

10.1.1. MARKET SIZE & ESTIMATES

10.1.2. KEY GROWTH ENABLERS

10.1.3. KEY CHALLENGES

10.1.4. KEY PLAYERS

10.1.5. COUNTRY ANALYSIS

10.1.5.1.    UNITED STATES

10.1.5.2.    CANADA

10.2. EUROPE

10.2.1. MARKET SIZE & ESTIMATES

10.2.2. KEY GROWTH ENABLERS

10.2.3. KEY CHALLENGES

10.2.4. KEY PLAYERS

10.2.5. COUNTRY ANALYSIS

10.2.5.1.    UNITED KINGDOM

10.2.5.2.    GERMANY

10.2.5.3.    FRANCE

10.2.5.4.    SPAIN

10.2.5.5.    ITALY

10.2.5.6.    NORDIC COUNTRIES

10.2.5.7.    REST OF EUROPE

10.3. ASIA-PACIFIC

10.3.1. MARKET SIZE & ESTIMATES

10.3.2. KEY GROWTH ENABLERS

10.3.3. KEY CHALLENGES

10.3.4. KEY PLAYERS

10.3.5. COUNTRY ANALYSIS

10.3.5.1.    CHINA

10.3.5.2.    JAPAN

10.3.5.3.    INDIA

10.3.5.4.    SOUTH KOREA

10.3.5.5.    INDONESIA

10.3.5.6.    THAILAND

10.3.5.7.    VIETNAM

10.3.5.8.    AUSTRALIA

10.3.5.9.    REST OF ASIA-PACIFIC

10.4. REST OF WORLD

10.4.1. MARKET SIZE & ESTIMATES

10.4.2. KEY GROWTH ENABLERS

10.4.3. KEY CHALLENGES

10.4.4. KEY PLAYERS

10.4.5. REGIONAL ANALYSIS

10.4.5.1.    LATIN AMERICA

10.4.5.2.    MIDDLE EAST & AFRICA

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS

11.1.1. MERGERS & ACQUISITIONS

11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS

11.1.3. PARTNERSHIPS & AGREEMENTS

11.1.4. BUSINESS EXPANSIONS & DIVESTITURES

11.2. COMPANY PROFILES

11.2.1. ADMA BIOLOGICS

11.2.2. BIO PRODUCTS LABORATORY

11.2.3. BIOTEST AG

11.2.4. CHINA BIOLOGIC PRODUCTS INC

11.2.5. CSL BEHRING

11.2.6. GRIFOLS SA

11.2.7. KAMADA LTD

11.2.8. KEDRION BIOPHARMA

11.2.9. LFB GROUP

11.2.10. OCTAPHARMA AG

11.2.11. PFIZER INC

11.2.12. SANQUIN PLASMA PRODUCTS BV

11.2.13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

11.2.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

11.2.15. TAKEDA PHARMACEUTICAL COMPANY LIMITED

 

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - IMMUNOGLOBULIN

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: GLOBAL IMMUNOGLOBULIN MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 4: GLOBAL IMMUNOGLOBULIN MARKET, BY PRODUCT, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 5: GLOBAL IGG MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 6: GLOBAL IGG MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 7: GLOBAL IGA MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 8: GLOBAL IGA MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 9: GLOBAL IGM MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 10: GLOBAL IGM MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 11: GLOBAL IGE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 12: GLOBAL IGE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 13: GLOBAL IGD MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 14: GLOBAL IGD MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 16: GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 17: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 18: GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 19: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 20: GLOBAL SUBCUTANEOUS IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 21: GLOBAL INTRAMUSCULAR IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 22: GLOBAL INTRAMUSCULAR IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 23: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 24: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 25: GLOBAL HYPOGAMMA GLOBULINEMIA MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 26: GLOBAL HYPOGAMMA GLOBULINEMIA MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 27: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 28: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 29: GLOBAL PRIMARY IMMUNODEFICIENCY DISEASES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 30: GLOBAL PRIMARY IMMUNODEFICIENCY DISEASES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 31: GLOBAL MYASTHENIA GRAVIS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 32: GLOBAL MYASTHENIA GRAVIS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 33: GLOBAL MULTIFOCAL MOTOR NEUROPATHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 34: GLOBAL MULTIFOCAL MOTOR NEUROPATHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 35: GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 36: GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 37: GLOBAL INFLAMMATORY MYOPATHIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 38: GLOBAL INFLAMMATORY MYOPATHIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 39: GLOBAL SPECIFIC ANTIBODY DEFICIENCY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 40: GLOBAL SPECIFIC ANTIBODY DEFICIENCY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 41: GLOBAL GUILLAIN-BARRE SYNDROME MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 42: GLOBAL GUILLAIN-BARRE SYNDROME MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 43: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 44: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 45: GLOBAL IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 46: GLOBAL IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 47: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 48: GLOBAL HOSPITAL PHARMACY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 49: GLOBAL SPECIALTY PHARMACY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 50: GLOBAL SPECIALTY PHARMACY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 51: GLOBAL OTHER DISTRIBUTION CHANNELS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 52: GLOBAL OTHER DISTRIBUTION CHANNELS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 53: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 54: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 55: GLOBAL HOSPITALS & CLINICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 56: GLOBAL HOSPITALS & CLINICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 57: GLOBAL HOMECARE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 58: GLOBAL HOMECARE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 59: GLOBAL IMMUNOGLOBULIN MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 60: GLOBAL IMMUNOGLOBULIN MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 61: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 62: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 63: LEADING PLAYERS OPERATING IN NORTH AMERICA IMMUNOGLOBULIN MARKET

TABLE 64: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 65: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 66: LEADING PLAYERS OPERATING IN EUROPE IMMUNOGLOBULIN MARKET

TABLE 67: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 68: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 69: LEADING PLAYERS OPERATING IN ASIA-PACIFIC IMMUNOGLOBULIN MARKET

TABLE 70: REST OF WORLD IMMUNOGLOBULIN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 71: REST OF WORLD IMMUNOGLOBULIN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 72: LEADING PLAYERS OPERATING IN REST OF WORLD IMMUNOGLOBULIN MARKET

TABLE 73: LIST OF MERGERS & ACQUISITIONS

TABLE 74: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 75: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 76: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

 

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: VENDOR LANDSCAPE

FIGURE 5: KEY BUYING CRITERIA

FIGURE 6: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021

FIGURE 7: GLOBAL IMMUNOGLOBULIN MARKET, BY IGG, 2022-2030 (IN $ MILLION)

FIGURE 8: GLOBAL IMMUNOGLOBULIN MARKET, BY IGA, 2022-2030 (IN $ MILLION)

FIGURE 9: GLOBAL IMMUNOGLOBULIN MARKET, BY IGM, 2022-2030 (IN $ MILLION)

FIGURE 10: GLOBAL IMMUNOGLOBULIN MARKET, BY IGE, 2022-2030 (IN $ MILLION)

FIGURE 11: GLOBAL IMMUNOGLOBULIN MARKET, BY IGD, 2022-2030 (IN $ MILLION)

FIGURE 12: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY MODE OF DELIVERY, IN 2021

FIGURE 13: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 14: GLOBAL IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 16: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021

FIGURE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2030 (IN $ MILLION)

FIGURE 18: GLOBAL IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2030 (IN $ MILLION)

FIGURE 19: GLOBAL IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2030 (IN $ MILLION)

FIGURE 20: GLOBAL IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2030 (IN $ MILLION)

FIGURE 21: GLOBAL IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2030 (IN $ MILLION)

FIGURE 22: GLOBAL IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2030 (IN $ MILLION)

FIGURE 23: GLOBAL IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2030 (IN $ MILLION)

FIGURE 24: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2030 (IN $ MILLION)

FIGURE 25: GLOBAL IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2030 (IN $ MILLION)

FIGURE 26: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)

FIGURE 27: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2021

FIGURE 28: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2030 (IN $ MILLION)

FIGURE 29: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2030 (IN $ MILLION)

FIGURE 30: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER DISTRIBUTION CHANNELS, 2022-2030 (IN $ MILLION)

FIGURE 31: GLOBAL IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

FIGURE 32: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)

FIGURE 33: GLOBAL IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2030 (IN $ MILLION)

FIGURE 34: NORTH AMERICA IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 35: UNITED STATES IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 36: CANADA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 37: EUROPE IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 38: UNITED KINGDOM IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 39: GERMANY IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 40: FRANCE IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 41: SPAIN IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 42: ITALY IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 43: NORDIC COUNTRIES IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 44: REST OF EUROPE IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 45: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 46: CHINA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 47: JAPAN IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 48: INDIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 49: SOUTH KOREA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 50: INDONESIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 51: THAILAND IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 52: VIETNAM IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 53: AUSTRALIA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 54: REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 55: REST OF WORLD IMMUNOGLOBULIN MARKET, REGIONAL OUTLOOK, 2021 & 2030 (IN %)

FIGURE 56: LATIN AMERICA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 57: MIDDLE EAST & AFRICA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

 

KEY FINDINGS

The global immunoglobulin market is anticipated to rise with a CAGR of 6.87% across the forecast years of 2022 to 2030. The market’s growth is strengthened by the increasing incidence of autoimmune disorders as well as immunodeficiency diseases, the rise in the geriatric populace, and the growing research and development activities.

 

Get more Insights into the Global Immunoglobulin Market:

https://inkwoodresearch.com/reports/immunoglobulin-market/

 

MARKET INSIGHTS

Immunoglobulins are characterized as antibodies that are produced naturally by the body’s immune system. They primarily help fight diseases and infections. These glycoprotein molecules are generated by plasma cells and also act as a pivotal component of the immune response of the body.

The rise in the geriatric population across the world is a leading factor expected to fuel the global immunoglobulin market growth over the forecasted years. As an individual ages, their immune system tends to deteriorate and responds relatively slower. This factor significantly increases the risk of sickness.

Moreover, the loss of adaptive immunity entailing older age not only makes a person more vulnerable to infections but also reactivates dormant pathogens that were formerly suppressed. As a result, the senior population is at a higher risk of an increased incidence of immunodeficiency diseases as well as the severity of certain infections. Hence, the growth in the elderly is set to augment the prevalence of age-related diseases, subsequently increasing the need for immunoglobulin products for their treatment.

 

REGIONAL INSIGHTS

The global immunoglobulin market growth assessment comprises the evaluation of North America, Europe, Asia-Pacific, and Rest of World. The Asia-Pacific is expected to be the fastest-growing region during the forecast years. The regional market’s growth is mainly ascribed to the surging prevalence of different types of diseases, the increasing elderly population, and the surge in research and development.

 

COMPETITIVE INSIGHTS

The competitive rivalry within the global immunoglobulin market is intense and is anticipated to remain high during the forecast period. Furthermore, the presence of numerous leading market players across various regions facilitates a higher level of competition since the industry is fragmented. Some of the key players operating in the market are Pfizer Inc, Kamada Ltd, LFB Group, etc.

 

Our report offerings include:

·       Explore key findings of the overall market

·       Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

·       Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

·       Market Segmentation cater to a thorough assessment of key segments with their market estimations

·       Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

·       Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

·       Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

·       Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

 

SEGMENTATION

1.     ADMA BIOLOGICS

2.     BIO PRODUCTS LABORATORY

3.     BIOTEST AG

4.     CHINA BIOLOGIC PRODUCTS INC

5.     CSL BEHRING

6.     GRIFOLS SA

7.     KAMADA LTD

8.     KEDRION BIOPHARMA

9.     LFB GROUP

10. OCTAPHARMA AG

11. PFIZER INC

12. SANQUIN PLASMA PRODUCTS BV

13. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

15. TAKEDA PHARMACEUTICAL COMPANY LIMITED

 

Comments

Post a Comment

Popular posts from this blog

High Voltage Cable Market: Major End-Users Augment Demands

Image
  High voltage cables (HVCs) are the backbone of electrical infrastructure globally. From their use in commercial and residential infrastructures to industrial end uses in mining, oil & gas factories, power & utilities, etc., HVCs are crucial supplements to the growth of the power sector. Besides, urbanization and industrialization globally are increasing the demand for electric power. Therefore, the surging power demand is expected to result in more power generation and transmission, thereby propelling the requirement for high voltage cables. Inkwood Research predicts that the global high voltage cable market is set to surge with a 5.12% CAGR during the forecast period 2023-2032 .   High Voltage Cable Market: Major End Uses HVCs are extensively utilized for high voltage electric power transmission. Equipped with multiple conductors, structural elements of protective jackets, and insulators, they are designed to transmit electricity efficiently without long-ra...
Read more

UAV Battery Market: Military & Commercial Applications direct Growth

Image
  Unmanned aerial vehicles (UAVs) or automated drones fly for long periods at a controlled speed and height and have a role in many aspects of aviation. They are used in various functions, ranging from food delivery, filming, photography, climate change monitoring, and search operations after natural disasters. With the growing geo-political tension among major countries, UAVs have gained massive demand. This is because drones are used by the military worldwide for surveillance, reconnaissance, and targeted attacks. These devices operate wirelessly, creating a huge requirement for UAV batteries for optimal use. Accordingly, as per our research, the   global UAV battery market   is estimated to generate a whopping   $17.7 billion   in revenue, with a   16.32% CAGR   during the forecast years,   2022-2030 .   UAV Battery: Growing Military Applications Militaries need UAVs for training in combat situations and ISR (intelligence, surveillance, an...
Read more

X-Ray Tube Market: Trending Applications & Novel Developments

Image
 X-ray tube, also known as a Roentgen tube, functions as a specific energy converter that receives electrical energy and converts it into heat (99%) and x-radiation (1%). The primary function of an X-ray tube is to create x-ray photons from electric energy transmitted by the x-ray generator. As per Inkwood Research, the global X-ray tube market is forecasted to rise with a CAGR of 3.81% during the projected years of 2022 to 2030 . Their widespread usage across applications, such as material and structure analysis, CT scanners, X-ray crystallography, and airport luggage scanners, among others, play an essential role in surging the demand and adoption of X-ray tubes worldwide.   X-Ray – An Incredible Contribution to Human Health The discovery of the X-ray in 1895 provided physicians with an effective, non-surgical tool to analyze the inside of the human body. Moreover, following the development of the ‘Coolidge tube’ in 1913, which continues to remain the model that...
Read more